XNAS · Healthcare · Biotechnology
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
Immatics posted a weak quarter: revenue of **$11M** missed by **$4M** and EPS was **$-0.53**, worse than the **$-0.43** estimate. In biotech, the lack of a catalyst and a **-407%** margin underscore heavy cash burn and an unconvincing commercial profile.
AI-generated summary — powered by BigEarnings.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-18 | Q2 2026 | -0.43 | -0.53 | -23.26% | $10.6M | ❌ Miss | -0.54% | +1.65% | — |
| 2026-05-12 | Q1 2026 | -0.42 | -0.50 | -19.05% | $8.9M | ❌ Miss | -0.52% | -6.06% | -20.46% |
| 2026-03-05 |
| Q4 2025 |
| -0.48 |
| -0.34 |
| +29.17% |
| $23.0M |
| ✅ Beat |
| -2.65% |
| -7.29% |
| +1.97% |
| 2025-11-17 | Q3 2025 | -0.50 | -0.49 | +2.00% | $6.1M | ✅ Beat | — | — | — |
| 2025-08-13 | Q2 2025 | -0.38 | -0.66 | -73.68% | $5.5M | ❌ Miss | -6.23% | -8.20% | -4.59% |
| 2025-03-27 | Q4 2024 | — | 0.48 | — | $60.0M | — | -1.70% | -18.47% | +1.27% |
| 2024-11-18 | Q3 2024 | -0.29 | -0.12 | +58.62% | $55.6M | ✅ Beat | -0.13% | -2.94% | -13.94% |
| 2024-08-13 | Q2 2024 | -0.31 | -0.18 | +41.94% | $20.2M | ✅ Beat | +1.74% | +2.09% | +8.25% |
Showing last 8 quarters.